B7-33 dosing
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
B7-33 is a relaxin analogue administered by subcutaneous injection in research. The values below are a generalized reference from preclinical data and protocols (no validated human regimens exist).
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (week 1) | 100 mcg, once daily | Starting dose |
| Maintenance | 100–250 mcg, once daily | Increase if needed |
| Maximum in schedule | 250 mcg, once daily | Maximum in this schedule |
| Cycle length | 4–8 weeks | , |